Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker-Reply

JAMA Oncol. 2021 Aug 1;7(8):1245-1246. doi: 10.1001/jamaoncol.2021.1870.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Biomarkers, Tumor / genetics
  • Humans
  • Immunotherapy*
  • Mutation
  • Neoplasms* / genetics
  • Neoplasms* / pathology
  • Neoplasms* / therapy

Substances

  • Biomarkers, Tumor